Heart Failure Management

Heart failure is a clinical syndrome in which the heart cannot pump efficiently enough to meet the body's demands — or can only do so at abnormally elevated filling pressures. The result is breathlessness, ankle swelling, and fatigue. It is not a disease in itself but a consequence of underlying conditions — most commonly coronary artery disease, hypertension, or valve disease. Modern guideline-directed therapy has transformed heart failure into a manageable chronic condition where mortality can be reduced by over 50% with optimal treatment.

Ejection fraction (EF) is the percentage of blood pumped out of the left ventricle with each heartbeat, measured by echocardiography. Normal EF is 55–70%. Heart failure is classified by EF: HFrEF (EF <40%), HFmrEF (EF 40–49%), and HFpEF (EF ≥50%). The classification determines treatment — HFrEF responds strongly to all four GDMT pillars with proven mortality benefits. HFpEF is managed differently, primarily with SGLT2 inhibitors and risk factor control.

The four pillars of GDMT for HFrEF are: (1) ACEi/ARNi — sacubitril-valsartan; (2) Beta-blockers — bisoprolol, carvedilol, or metoprolol succinate; (3) MRA — spironolactone or eplerenone; (4) SGLT2 inhibitors — dapagliflozin or empagliflozin. All four classes together produce additive benefits, reducing cardiovascular mortality by over 55% compared with placebo.

SGLT2 inhibitors (dapagliflozin, empagliflozin) were originally diabetes medications but were found in large trials to dramatically reduce heart failure outcomes independent of glucose lowering. DAPA-HF (NEJM 2019) showed dapagliflozin reduced worsening HF or CV death by 26% in HFrEF patients — including those without diabetes. They are now recommended for all HFrEF patients, regardless of diabetes status.

Yes — heart failure can improve significantly with optimal guideline-directed medical therapy (GDMT). The four pillars of treatment — ARNi/ACEi, beta-blockers, MRAs, and SGLT2 inhibitors — work together to reduce the workload on the heart, block harmful neurohormonal activation, and promote reverse cardiac remodelling. Many patients experience improvement in ejection fraction (sometimes normalising from severely reduced levels), reduction in heart size, and resolution of symptoms. This is called 'heart failure with recovered EF'. However, heart failure remains a chronic condition — even when EF normalises, medication is typically continued lifelong to maintain the improvement and prevent recurrence.

Fluid management in heart failure depends on the severity of the condition. For patients with stable, well-compensated heart failure, a standard fluid intake of 1.5–2 litres per day is generally acceptable. For patients with moderate-to-severe heart failure, especially those requiring high-dose diuretics or with recurrent fluid overload, fluid restriction to 1.5 litres per day is often recommended. More importantly than fluid intake, salt restriction below 5 g per day is critical — salt drives fluid retention. Daily weight measurement is the most practical way to monitor fluid status: a weight gain of more than 2 kg in 3 days indicates fluid overload requiring medical attention.

Yes — regular exercise is not only safe for most patients with stable heart failure, it is strongly recommended. Exercise training improves exercise capacity, quality of life, and reduces hospitalisation rates. The ESC recommends at least 30 minutes of moderate-intensity aerobic exercise (such as brisk walking or stationary cycling) on most days, supplemented by resistance training twice weekly. Cardiac rehabilitation programmes provide supervised, individualised exercise prescription. Patients should avoid heavy lifting, straining, and high-intensity isometric exercises — particularly those with reduced EF or device implants. Always obtain clearance from your cardiologist before starting an exercise programme, especially if you have advanced heart failure.

End-stage (Stage D) heart failure is advanced heart failure with persistent severe symptoms despite maximal medical therapy and device optimisation. Options include advanced therapies and palliative care. Left ventricular assist devices (LVADs) are mechanical pumps that support the failing heart — used as a bridge to transplant or as destination therapy. Heart transplantation remains the definitive treatment for eligible candidates. For patients who are not candidates for advanced therapies, palliative care focused on symptom management, quality of life, and advance care planning is an essential component. Continuous inotropic support at home may be considered in select cases. Early referral to a heart failure specialist centre is critical for patients with advanced disease.